New therapies for dedifferentiated papillary thyroid cancer
Open accessAbstract
The number of thyroid cancers is increasing. Standard treatment usually includes primary surgery, thyroid-stimulating hormone suppressive therapy, and ablation of the thyroid remnant with radioactive iodine (RAI). Despite the generally good prognosis of thyroid carcinoma, about 5% of patients will develop metastatic disease, which fails to respond to RAI, exhibiting a more aggressive behavior. The lack of specific, effective and well-tolerated drugs, the scarcity of data about the association of multi-targeting drugs, and the limited role of radioiodine for dedifferentiated thyroid cancer, call for further efforts in the field of new drugs development. Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, BRAF (B-RAF proto-oncogene, serine/threonine kinase) gene mutations, RAS (rat sarcoma) mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the known pathways playing a crucial role in the development of thyroid cancer. Targeted novel compounds have been demonstrated to induce clinical responses and stabilization of disease. Sorafenib has been approved for differentiated thyroid cancer refractory to RAI.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cellular dedifferentiation in thyroid carcinoma is accompanied by more aggressive growth, recurrence, distant metastasis, and resistance to RAI.
“Cellular dedifferentiation generally occurs in cases accompanied by more aggressive growth, recurrence, distant metastasis, and resistance to RAI [1, 8–10].”
From Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells (2017) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 190 · Cited by 58
Research works printed but not linked: 1
- [98]Hu-Lowe D. Hallin M. Feeley R. Zou H. Rewolinski D. Wickman G. Chen E. Kim Y. Riney S. Reed J. Characterization of potency and activity of the VEGF/PDGF receptor tyrosine kinase inhibitor AG013736 Proc. Am. Assoc. Cancer Res. 2002 43 A5356
- Authors
- Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A.
- Affiliations
- University of Pisa (IT)
- University of Messina (IT)
- Corresponding author
- Antonelli, Alessandro
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-03-17
- Volume
- 16
- Issue
- 3
- Pages
- 6153-6182
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC4394525
- OpenAlex
- W1966784294
- Cited by
- 58
- References
- 190
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 4 · 2020: 4 · 2019: 2 · 2018: 9 · 2017: 4 · 2016: 8 · 2015: 9
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Keywords
- RET/PTC rearrangement, BRAF mutation, RAS mutations, sorafenib, radioiodine-refractory thyroid cancer, targeted therapy, metastatic thyroid cancer, drug development
- MeSH terms
- Thyroid Cancer, Papillary, Proto-Oncogene Mas, Antineoplastic Agents, Carcinoma, Carcinoma, Papillary, Humans, Neoplasm Staging, Thyroid Neoplasms, ras Proteins, Drug Resistance, Neoplasm, Vascular Endothelial Growth Factor A, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-ret, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
